Merck Sharp + Dohme Corp.

Dragonfly Therapeutics, Inc.

Adimab, LLC

Surface Oncology, Inc.

Cancer Research Technology Limited

Tusk Therapeutics Ltd.

Black Belt Therapeutics Limited

University of Texas System

Mersana Therapeutics, Inc.

Novartis Ag

Seagen Inc.

Arsanis Biosciences Gmbh

Bianka Prinz

Josephine Salimu

Beatriz Goyenechea Corzo

Kevin Moulder

Pascal Merchiers

Anne Goubier

William Haney

Dongxing Zha

Ann F Cheung

Gregory P Chang

Bradley M Lunde

Asya Grinberg

Sergio Quezada

Kenneth Ellsworth

Mark Brown

Dietmar Seiffert

James Milligan

Elizabeth Oldham

Nadthakarn Boland

James Geoghegan

Zhu Chen

Hemanta Baruah

Simone Filosto

Nina Eissler

Scott C Chappel

Pamela M Holland

Andrew Lake

Michael A Curran

Carlo Toniatti

Ashvin R Jaiswal

Eric Krauland

Kui Shin Voo

Natarajan Sethuraman

Matthew Rausch

Piotr Bobrowicz

Stefan Wildt

Daniel Fallon

Vaishnavi Ganti

Mohammad Tabrizifard

Ronnie Wei

Steven O'Neil

Michael Warren

Timothy B Lowinger

Aleksandr V Yurkovetskiy

Peter U Park

Natalya D Bodyak

Nicolai Wagtmann

Nels P Nielson

Jonathan Hill

Michael N Gladstone

Kevin Schutz

John Bukowski

Christine Miller

Michael J DeVit

Austin Dulak

Erik Devereaux

Tauqeer Zaidi

Sonia Das

Jennifer Symonds

James Mohan

Marisella Panduro Sicheva

Kerry White

Jing Hua

Devapregasan Moodley

Eszter Nagy

Byung-Kwon Choi

Gábor Nagy

Terrance A Stadheim

Shyra Gardai

Irina Mirkina

Adriana Badarau

Scott Peterson

Alison Paterson

Michael A Meehl

Jerry M Thomas

Ansgar Brock

Zoltán Magyarics

Manuel Zerbs

Astrid Teubenbacher

Zehra Visram

Wei Shu

Eva Gutierrez

Harald Rouha

Lukas Stulik

Rachel W O'Connor

Michaela Jaegerhofer

Ivana Dolezilkova

Dirksen Bussiere

Michael Benjamin Battles

Mikias Woldegiorgis

Alison M O'Neill

John Delmas Venable

Mitchell Bigelow

Julia C Piasecki

Jinyan Du

Nga Rewa Houston

Dhruv Kam Sethi

Courtney Beers

Gege Tan

Michael J Devit

The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Human PD-L2 antibodies and methods of use therefor

Combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen

Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Proteins binding NKG2D, CD16 and a tumor-associated antigen

The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Anti-IL-27 antibodies and uses thereof

The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

CD38 modulating antibody agents

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Human PD-L1 antibodies and methods of use therefor

CD38 modulating antibody

Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.

Anti-coagulation factor XI antibodies

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.

Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use

Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

Antibody variable domains targeting the NKG2D receptor

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.

Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

The invention provides anti-CD112R antibody compositions and their use in treating cancer.

Anti-CD112R compositions and methods

CD38 antibody

Growing community of inventors

Lebanon, NH, United States of America

Bianka Prinz